L'intérêt à découvert pour HCW Biologics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de HCW Biologics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

HCW Biologics (NASDAQ:HCWB) Stock, Rapport sur les intérêts à découvert

HCW Biologics

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

HCW Biologics Inc

DA Davidson analyst Linda Bolton Weiser maintains WD-40 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) with a Buy and maintains $322 price target.

News

Price Target

Analyst Ratings

WDFC

DA Davidson Maintains Buy on WD-40, Maintains $322 Price Target

Tigress Financial analyst Ivan Feinseth maintains Booking Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) with a Strong Buy and raises the price target from $4580 to $5600.

BKNG

Tigress Financial Maintains Strong Buy on Booking Holdings, Raises Price Target to $5600

Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) today announced that funds associated with its Impact and Clean Transition strategies (the "Apollo Funds") have acquired a majority stake in The State Group ("TSG" or the "Company") from Blue Wolf Capital ("Blue Wolf"). Blue Wolf will retain a minority stake in the business, alongside existing management shareholders.
Established in 1961, TSG is a leading provider of electrical, mechanical, robotics and automation services, with a strong presence across industrial end markets. TSG executes complex projects at facilities from newbuild to ongoing maintenance and retrofit with decades-long customer relationships across key markets. A substantial portion of the Company's work enables customers to optimize, reduce and decarbonize their energy use, helping a wide range of industrial end markets abate future emissions. The Company plays an important role in enabling the energy transition through its expertise in industrial manufacturing plants as well as power and renewable facilities. TSG's capabilities have clear applicability to a number of fast-growing end markets, including data centers, where the Company supports critical technology infrastructure by providing electrical contracting services and other specialized solutions.

Apollo Funds Acquire Majority Stake In The State Group From Blue Wolf Capital; Blue Wolf Will Retain A Minority Stake In The Business, Alongside Existing Management Shareholders; No Financial Terms Disclosed

The post-election landscape raises uncertainty for cannabis MSOs, with investors hoping for potential relief from the new administration. Verano (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VRNOF#OTC">VRNOF</a>), Green Thumb (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GTBIF#OTC">GTBIF</a>), and Gold Flora (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GRAM#OTCQB">GRAM</a>) show mixed results, balancing strategic gains with regulatory challenges. While full federal legalization remains a distant possibility, Pablo Zuanic, from Zuanic &amp; Associates, suggests a gradual shift towards rescheduling cannabis to Schedule III, potentially extending into late 2025.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can't afford to miss out if you&#8217;re serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Verano Holdings: Market Headwinds</h3>
Verano posted Q3 results reflecting a mixed performance, with $227 million in sales, marking a 5% sequential decline. The drop was partly attributed to seasonality and market pressures in key states like Florida. Despite acquiring assets from The Cannabist Company (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CBSTF#OTC">CBSTF</a>), which were only partially reflected in Q3, Verano&#8217;s financial health is strained by a high debt burden—standing at 40% of the last twelve months (LTM) sales, and substantial tax liabilities of 32%. Adjusted EBITDA margins fell by 200 basis points to 30%, indicating pressure on profitability​.
The company remains Overweight in<a href="https://www.benzinga.com/topic/pablo-zuanic"> Zuanic's ratings</a>, but concerns about its exposure to the Florida market may hinder short-term recovery, particularly given the state's rejection of adult-use legalization in the recent election. This has led to a 44% drop in Verano's stock post-election, highlighting the vulnerability of <a href="https://www.benzinga.com/topic/florida-cannabis">Florida-dependent operators</a>​.
<h3 class="wp-block-heading">Green Thumb Industries: Resilient But Cautious</h3>
Green Thumb reported a stronger Q3 performance, with $287 million in sales, up 2% sequentially. The company stands out with robust cash flow management, generating an adjusted operating cash flow of $139 million, representing 17% of sales.
With relatively low leverage—net debt at just 7% of LTM sales—and healthier <a href="https://www.benzinga.com/markets/cannabis/24/11/41832358/green-thumb-grows-revenue-to-287m-in-q3-expands-cannabis-retail-network">adjusted EBITDA margins of 31%</a>, Green Thumb appears well-positioned to navigate the current regulatory uncertainty.
In terms of financial leverage, Cresco Labs (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CRLBF#OTC">CRLBF</a>) carries the highest combined debt and tax liabilities at 80% of last twelve months (LTM) sales, followed closely by Curaleaf (OTC:<a class="ticker" href="https://www.benzinga.com/stock/CURLF#OTC">CURLF</a>) at 79% and Verano at 72%. Green Thumb, on the other hand, stands out with a low leverage ratio of 9% of LTM sales, bolstered by strong cash flow performance.
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41925770/three-paths-to-cannabis-profits-village-farms-green-thumb-and-jushi-show-divergent-"> Three Paths To Cannabis Profits: Village Farms, Green Thumb, And Jushi Show Divergent Strategies—Which Will Deliver?</a>
<h3 class="wp-block-heading">Gold Flora: Expansion Amidst Market Challenges</h3>
Gold Flora, a California-focused operator, showcased significant operational improvements in Q3 2024. The company's adjusted gross margins surged from 54% in Q1 to 65% in Q3, with EBITDA margins reaching 9%, a notable turnaround from -6% in the first half of the year. The brand's strategic push into the vaping segment, particularly with its Gramlin line, has been met with strong market reception, becoming a top-10 brand in <a href="https://www.benzinga.com/topic/california-cannabis">California</a>.
However, according to <a href="https://zuanicgroup.com/">Zuanic</a> Gold Flora's financial stability remains a concern. The company's debt obligations have increased, with tax liabilities now at $44 million, up from $28 million at year-end 2023. A planned expansion of indoor cultivation capacity by 50% and new store openings are aimed at bolstering revenue growth.
<h3 class="wp-block-heading">Benchmarking Tier 1 MSOs: Financial Health</h3>
<ul>
<li>EBITDA Margins: In Q3 2024, Trulieve led with a 34% EBITDA margin, followed by Green Thumb at 31%, and Verano at 30%, each down sequentially. Cresco held steady at 29%, while Curaleaf improved to 23%.</li>
<li>Cash Flow Performance: Green Thumb excelled with an adjusted operating cash flow (OCF) of $139 million (17% of sales). Trulieve and Verano followed with $37 million (4%) and $30 million (5%), respectively. Curaleaf broke even at $4 million, while Cresco lagged at -$3 million.</li>
<li>Valuation Comparisons: Green Thumb and Curaleaf trade at an EV-to-sales ratio of 2.2x. Trulieve is at 1.8x, with Cresco and Verano at 1.6x. For EV to EBITDA, Curaleaf leads at 10x, Green Thumb at 7x, and the rest between 5.2x and 5.5x.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/general/biotech/24/11/41997354/selling-weed-is-like-a-sneaker-drop-running-out-isnt-a-problem-for-this-company"> Selling Weed Is Like A Sneaker Drop: Running Out Isn&#8217;t A Problem For This Company</a>

Analyst Color

Cannabis

Macro Economic Events

Market Summary

Mid Cap

Retail Sales

Economics

Exclusives

Markets

Trading Ideas

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GRAM

GTBIF

VRNOF

Can Trump's Return Save The Cannabis Sector? Debt Mounts As Giants Face Post-Election Reckoning

ECARX Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) ("ECARX"), a global mobility tech provider, today announced that, on November 14, 2024, it entered into a components procurement and R&amp;D services agreement with Geely Automobile Holdings Limited (HKEX: 0175) ("Geely Auto"), Zhejiang HUANFU and Hangzhou Langge (the "Components Procurement and R&amp;D Services Agreement"), pursuant to which Geely Auto agrees to, subject to certain conditions set forth therein, purchase automobile components and R&amp;D services from the Company, Zhejiang HUANFU Technology Co., Ltd. and Hangzhou Langge Technology Co., Ltd. (collectively, the "Supplier Group") to further enhance the driving technology system for new energy vehicles of Geely Auto. The agreement has a term of three years and ends on December 31, 2027. The aggregated annual caps covered by the Components Procurement and R&amp;D Services Agreement – totaling RMB6,387.281 million, RMB6,430.855 million and RMB6,489.889 million for the Supplier Group for 2025, 2026 and 2027, respectively – will be exempt from the requirement of the approvals of independent shareholders of Geely Auto pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"); and the parties are not restrained from transacting beyond the exempt amounts under this agreement as long as Geely Auto has complied with the requirements under the Listing Rules. The rights and obligations of the parties to the agreement are subject to the fulfilment (or waiver, as applicable) of various conditions precedent.
The Company will continue to be a stable and reliable source of automobile components and R&amp;D support for the manufacturing of new energy vehicles for brands within Geely Auto, such as ZEEKR and LYNK &amp; CO, under the Components Procurement and R&amp;D Services Agreement. Beyond this, ECARX remains committed to serving brands outside Geely Auto, such as Volvo, smart, Lotus and Polestar, and expanding its global footprints within and without Geely Auto.

Contracts

ECARX Signs 3-Year Components Procurement And R&D Services Agreement With Geely Auto; The Aggregated Annual Caps Covered By The Services Agreement, Totaling RMB6,387.281 Million, RMB6,430.855 Million And RMB6,489.889 Million For The Supplier Group For 2025, 2026 And 2027, Respectively

INCY

Incyte Says Data From Phase 2 Study Evaluating MRGPRX4 (INCB000547) In Cholestatic Pruritus Does Not Support Further Development

MicroStrategy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares are moving in extended trading Monday after rallying about 13% during regular trading hours. Here&#8217;s what <a href="https://www.benzinga.com/trading-ideas/movers/24/11/42047385/microstrategy-shares-are-surging-monday-whats-going-on">you need to know</a>.
What To Know: After the market close on Monday, MicroStrategy announced a proposed private offering of $1.75 billion worth of its 0% convertible senior notes due 2029. 
The company will offer the shares in a private offering to qualified institutional buyers. MicroStrategy also plans to grant the initial purchasers a three-day period to purchase up to an additional $250 million worth of the notes. 
MicroStrategy said it intends to use the net proceeds from the offering to buy more Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
See Also: <a href="https://www.benzinga.com/general/social-media/24/11/42048594/trump-digs-deeper-into-cryptocurrency-bakkt-shares-soar-on-reported-interest-from-president-elects-media-company">Trump Digs Deeper Into Cryptocurrency? Bakkt Shares Soar On Reported Interest From President-Elect&#8217;s Media Company</a>
The offering follows a regulatory filing from Monday morning showing that MicroStrategy acquired approximately 51,780 Bitcoin between Nov. 11 and Nov. 17 for $4.6 billion in cash.
The purchases were funded using proceeds from the sales agreement the company entered into at the end of October. MicroStrategy said it had approximately $15.3 billion remaining under the sales agreement as of Nov. 17.
As of Sunday, MicroStrategy held a total of 331,200 Bitcoin purchased at an average price of approximately $49,874 per coin.
MicroStrategy co-founder and executive chairman Michael Saylor posted a <a href="https://x.com/saylor/status/1858247587951788410">poll on X</a> over the weekend asking whether Bitcoin would break through $100,000 by the end of the year. &#8220;Yes&#8221; was the answer of 85.6% of respondents.
MSTR Price Action: MicroStrategy shares initially traded closed Monday up almost 13%. The stock was down 0.64% in after-hours, trading at $382.33 at the time of writing, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42047066/goldman-sachs-to-spin-out-digital-assets-platform-amid-blockchain-push">Goldman Sachs To Spin Out Digital Assets Platform Amid Blockchain Push</a></li>
</ul>
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

After-Hours Center

Movers

$BTC

MSTR

What's Going On With MicroStrategy Stock Monday?

The decision was made following the observation of certain in vivo preclinical toxicology findings.
These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte will work closely with the FDA to determine next steps.
&nbsp;
&nbsp;

Incyte To Pause Enrollment In Ongoing Phase 2 Study Of MRGPRX2 (INCB000262) In Chronic Spontaneous Urticaria;

LANC

Lancaster Colony To Acquire Sauce and Dressing Production Facility For ~$75M

NW Natural Holdings To Acquire  SiEnergy Operating From SiEnergy Capital Partners For $273M In Cash And The Assumption Of $152M In Debt

Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psoriasis
74% of patients achieved clear or almost clear skin (IGA 0/1) at week 24
Comprehensive results are being prepared for presentation at upcoming medical congresses
SPRING HOUSE, Pa., Nov. 18, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced positive topline results from <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=1172454155&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095115&amp;a=ICONIC-LEAD">ICONIC-LEAD</a>a, a&nbsp;pivotal Phase 3 investigational study of icotrokinra (JNJ-2113), the first targeted oral peptide that selectively blocks the IL-23 receptor, in adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO). The Phase 3 study met its co-primary endpoints of Psoriasis Area and Severity Index (PASI) 90b and Investigator's Global Assessment (IGA) of 0/1c response at week 16 and response rates continued to improve through week 24.1
Once daily icotrokinra showed significant skin clearance versus placebo in adults and adolescents with moderate to severe plaque psoriasis. At week 16, nearly two-thirds (64.7%) of patients treated with&nbsp;icotrokinra achieved IGA scores of 0/1 (clear or almost clear skin), and 49.6% achieved PASI 90, compared to 8.3% and 4.4% on placebo, respectively.1 Further increases in response rates continued to be observed at week 24, with 74.1% of patients treated with icotrokinra achieving IGA scores of 0/1, and 64.9%&nbsp;achieving PASI 90.1&nbsp;Safety data was found to be consistent with the Phase 2 FRONTIER 1 and 2 studies. A similar proportion of patients experienced adverse events (AEs) between icotrokinra and placebo, with 49.3% and 49.1% of participants experiencing a treatment emergent adverse event (TEAE) at week 16.1,2,3
Furthermore, positive topline results from the Phase 3 <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4305031-1&amp;h=4201851419&amp;u=https%3A%2F%2Fclinicaltrials.gov%2Fstudy%2FNCT06095102&amp;a=ICONIC-TOTAL">ICONIC-TOTAL</a>d&nbsp;study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo.4 Comprehensive results from ICONIC-LEAD and ICONIC-TOTAL are being prepared for presentation at upcoming medical congresses and will be shared with health authorities in planned submissions.

Biotech

General

Johnson & Johnson Announced Topline Results From ICONIC-LEAD, A Pivotal Phase 3 Investigational Study Of Icotrokinra, The First Targeted Oral Peptide That Selectively Blocks The IL-23 Receptor, In Adults And Adolescents 12 Years Of Age And Older With Moderate To Severe Plaque Psoriasis; Met Its Co-Primary Endpoints In Patients With Moderate To Severe Plaque Psoriasis; 74% Of Patients Achieved Clear Or Almost Clear Skin At Week 24

Guidance

Archer-Daniels Midland Sees FY24 Adj. EPS $4.50-$5.00 Vs $4.60 Est.

Berquist, who succeeds Andy Tometich as Chief Executive Officer&nbsp;and President, most recently served as Executive Vice President and Chief Commercial Officer for Quaker Houghton.

Management

Quaker Houghton Board Appoints Joseph Berquist As CEO And President, And A Member Of Board, Effective Immediately

Archer-Daniels Midland (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) reported quarterly earnings of $1.09 per share which missed the analyst consensus estimate of $1.25 by 12.8 percent. The company reported quarterly sales of $19.937 billion which missed the analyst consensus estimate of $21.345 billion by 6.59 percent. This is a 8.10 percent decrease over sales of $21.695 billion the same period last year.

Earnings

Earnings Misses

Archer-Daniels Midland Q3 2024 Adj. EPS $1.09 Misses $1.25 Estimate, Sales $19.937B Miss $21.345B Estimate

Wendy's Appoints Ken Cook As CFO, Effective Dec. 2

Piper Sandler analyst Christopher Raymond upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Overweight and raises the price target from $3 to $13.

Upgrades

ACRS

Piper Sandler Upgrades Aclaris Therapeutics to Overweight, Raises Price Target to $13

Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42048131/symbotic-reports-fourth-quarter-and-fiscal-year-2024-results">details from the report.&nbsp;</a>
The Details:&nbsp;Symbotic reported quarterly earnings of five cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue came in at $576.76 million, which beat the analyst consensus estimate of $470.27 million and is an increase over sales of $391.88 million from the same period last year.
Read More: <a href="https://www.benzinga.com/etfs/24/11/42044642/trump-appears-frustrated-as-elon-musk-chimes-in-on-treasury-secretary-adds-more-names-to-a-list-of-potential-picks">Trump Appears &#8216;Frustrated&#8217; As Elon Musk Chimes In On Treasury Secretary, Adds More Names To Short List&nbsp;</a>
&#8220;I&#8217;m pleased with our performance this year, as our focus on innovation and customer success has delivered robust growth. This year&#8217;s results, driven by the hard work and dedication of our team, underscore the strength of our long-term strategy and commitment to driving sustainable, long-term growth for our customers, shareholders, and employees,&#8221; said Rick Cohen, CEO of Symbotic. 
Outlook:&nbsp;For the first quarter of fiscal 2025, Symbotic expects revenue of $495 million to $515 million, versus the $495.73 million estimate, and adjusted EBITDA of $27 million to $31 million.
SYM Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Symbotic shares are up 23.21% after-hours at $37.44 at the time of publication Monday.&nbsp;
Read More:  • <a href="https://www.benzinga.com/24/11/42047989/walmart-q3-earnings-preview-will-eps-beat-streak-continue-analysts-says-retailer-should-remain-a-core-holding">Will Walmart&#8217;s Streak Of Earnings Beats Continue Tuesday? Analysts Say Retailer A &#8216;Core Holding&#8217;</a>
Photo: Courtesy of Symbotic, Inc.

Symbotic Stock Rallies After Strong Q4 Results: Details

AMD Announces Darla Smith Resigns As Chief Accounting Officer, To Remain VP Until January 2025; Philip Carter Appointed As New Chief Accounting Officer

GBDC

Golub Capital BDC Reveals Series Of Debt Funding Structure Initiatives Expected To Reduce  Prospective Borrowing Costs And Provide Investment Flexibility

Investors and speculators are gearing up for Nvidia Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) earnings report on Wednesday, an event that&#8217;s expected to send ripples, if not tidal waves, <a href="https://www.benzinga.com/markets">across the U.S. stock market. </a>
If the options market is right, Nvidia's results could spark moves in the S&amp;P 500 index – as tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) – larger than those typically triggered by key economic data like the employment and inflation reports.
Nvidia's dominance in the AI-driven technology trade has turned its earnings into a barometer for overall market sentiment, and its influence on the stock market is unparalleled.
Over the past year, Nvidia accounted for 20% of the S&amp;P 500's total returns and Bank of America's derivatives analyst Gonzalo Asis didn't mince words: &#8220;It remains the most dominant stock in the market… expected to drive nearly 25% of the S&amp;P 500&#8217;s EPS growth in 3Q.&#8221;
In essence, whether Nvidia beats or misses expectations, the ripple effects will likely extend far beyond its ticker.
<h3 class="wp-block-heading">S&amp;P 500 Implied Move Is Higher Than Inflation Or Jobs Data</h3>
The options market implies a potential 1.05% move in the S&amp;P 500—higher than what traders expect from next month's Non-Farm Payroll (NFP) data, Consumer Price Index (CPI) print, and in line with the Federal Reserve&#8217;s December meeting.
&#8220;Options are assigning more broad-market risk around NVDA earnings than around next month&#8217;s NFP and CPI days, and as much as the Dec FOMC,&#8221; the analyst noted.
For Nvidia shares themselves, the implied one-day move is even more eye-popping: 12.5%.
&#8220;We remain cautious of fragility risks in single names around earnings, but NVDA hedges themselves are not particularly cheap relative to how much the stock has reacted to results in the last two years,&#8221; Assis wrote.
The analyst also warned that the recent easing of post-election euphoria and heightened single-stock fragility can be reasons for traders to hedge against potential market turbulence if Nvidia disappoints.
<h3 class="wp-block-heading">A Strategy For Hedging The Nasdaq Impact</h3>
For traders seeking to hedge the broader market risks tied to Nvidia&#8217;s performance, Bank of America recommended an option strategy using put spreads on the Nasdaq-100 ETF, the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>). Specifically, the QQQ 22Nov 490-480 put spreads are priced at $2 and could offer a 5x payout if the Nasdaq-100 falls by roughly 3.3% this week.
Despite the potential need for hedges, the bank also noted that hedging NVDA earnings directly is not cheap, considering how significantly the stock has reacted to its last few earnings reports.
<h3 class="wp-block-heading">Historical Nvidia Earnings Data</h3>
Data from <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111824&amp;t=be2bearmibe3na1">Benzinga Pro</a> shows that over the last 12 quarters, Nvidia has exceeded earnings-per-share (EPS) expectations 10 times and missed revenue expectations only once. 
On average, Nvidia shares moved 5.3% in the single trading day following its earnings release.
The largest 1-day gain followed its first quarter 2024 earnings, when the stock surged 24.4%, while the worst reaction occurred after fourth quarter 2024 results, with a decline of 7.6%. 
Here's a snapshot of the company's recent earnings performance:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>Fiscal Quarter</th>
<th>Date Announced</th>
<th>Surprise % EPS</th>
<th>Surprise % Revenue</th>
<th>1-Day % NVDA Move</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q2-2025</td>
<td>8/28/24</td>
<td>6.25%</td>
<td>4.73%</td>
<td>-6.38%</td>
</tr>
<tr>
<td>Q1-2025</td>
<td>5/22/24</td>
<td>2.86%</td>
<td>5.66%</td>
<td>9.32%</td>
</tr>
<tr>
<td>Q4-2024</td>
<td>2/21/24</td>
<td>11.45%</td>
<td>7.19%</td>
<td>16.40%</td>
</tr>
<tr>
<td>Q3-2024</td>
<td>11/21/23</td>
<td>19.64%</td>
<td>12.39%</td>
<td>-2.46%</td>
</tr>
<tr>
<td>Q2-2024</td>
<td>8/23/23</td>
<td>29.19%</td>
<td>20.38%</td>
<td>0.10%</td>
</tr>
<tr>
<td>Q1-2024</td>
<td>5/24/23</td>
<td>18.48%</td>
<td>10.31%</td>
<td>24.37%</td>
</tr>
<tr>
<td>Q4-2023</td>
<td>2/22/23</td>
<td>8.64%</td>
<td>0.68%</td>
<td>14.02%</td>
</tr>
<tr>
<td>Q3-2023</td>
<td>11/16/22</td>
<td>-15.94%</td>
<td>2.79%</td>
<td>-1.46%</td>
</tr>
<tr>
<td>Q2-2023</td>
<td>8/24/22</td>
<td>-59.20%</td>
<td>-17.23%</td>
<td>4.01%</td>
</tr>
<tr>
<td>Q1-2023</td>
<td>5/25/22</td>
<td>5.43%</td>
<td>2.07%</td>
<td>5.16%</td>
</tr>
<tr>
<td>Q4-2022</td>
<td>2/16/22</td>
<td>8.20%</td>
<td>3.01%</td>
<td>-7.56%</td>
</tr>
<tr>
<td>Q3-2022</td>
<td>11/17/21</td>
<td>6.36%</td>
<td>4.00%</td>
<td>8.25%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Data: Benzinga Pro</figcaption></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42042411/inflation-could-surge-to-3-if-trump-applies-universal-tariffs-goldman-sachs">Inflation Could Surge To 3% If Trump Applies Universal Tariffs: Goldman Sachs</a></li>
</ul>
Photo: Shutterstock

Equities

Broad U.S. Equity ETFs

Previews

Options

Econ #s

Federal Reserve

Tech

ETFs

NVDA

Why Nvidia Earnings May Trigger Massive S&P 500 Volatility

HCW Biologics reports Q2 results

Warning: HCWB is at high risk of performing badly

HCW Biologics reports Q3 results

HCW Biologics jumps on license agreement for immunotherapeutic product candidate

HCW Biologics (HCWB) and WY Biotech, a China-based company specializing in the early-stage development of recombinant protein drugs and gene/cell t...

HCW Biologics licenses proprietary preclinical molecule to WY Biotech

HCWB

Press Releases

HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results And Business Highlights

HCW Biologics Reports First Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Second Quarter 2024 Financial Results and Business Highlights

HCW Biologics Reports Third Quarter 2024 Financial Results and Business Highlights

HCW Biologics and WY Biotech Announce License Agreement  for Immunotherapeutic Product Candidate

Spotlight on Undervalued Nasdaq Stocks: HCWB, CRDL, NIVF, SINT, APLM – A Must-Watch This Week!

APLM

CRDL

NIVF

SINT

AIM ImmunoTech

Apollomics Inc. - Class A Ordinary Shares

Apollomics

Aprea Therapeutics

Alterity Therapeutics Limited - American Depositary Shares

Alterity Therapeutics

BioRestorative Therapies, Inc. - Common Stock

BioRestorative Therapies

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Ensysce Biosciences

Imunon

Immuron Limited - American Depositary Shares

Immuron

Indaptus Therapeutics, Inc. - Common Stock

Indaptus Therapeutics

Mustang Bio

Mainz Biomed

Minerva Neurosciences, Inc - Common Stock

Minerva Neurosciences

NKGen Biotech

Nanoviricides

Onconetix

BiomX

PharmaCyte Biotech

Palatin Techs

Sensei Biotherapeutics, Inc. - Common Stock

Sensei Biotherapeutics

Senti Biosciences

Synlogic

Tenax Therapeutics

Turnstone Biologics

XTL Biopharmaceuticals Ltd. - American Depositary Shares

XTL Biopharmaceuticals

EF Hutton

JonesTrading

Maxim Group

WIIM

HCW Biologics shares are trading higher after the company entered into an exclusive licensing deal with WY Biotech for immunotherapy development.

Comments

HCW Biologics

Intérêt court

HCW Biologics (NASDAQ:HCWB) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL